Save Product
Product Details
Product Details
Our Recombinant Human FGF basic Superior Stable Mutant Protein, developed via an AI-modified and experimentally validated closed-loop efficient protein design platform, is the optimal FGF2 mutant with superior thermal stability and activity compared to wild-type FGF2, making it more suitable for various stem cell culture processes. This reduces medium replacement frequency, lowers contamination risks from frequent operations, and saves costs/time for stem cell culture by minimizing reagent consumption and labor, especially in large-scale applications. This product is designed and developed utilizing our proprietary AI technology, which is protected by patent rights. We retain full commercial rights to this product.
It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.
Features and Advantages
- Engineered via a Closed-Loop AI Design Platform – Enables rational sequence optimization to achieve maximal functional performance.
- Protected by PCT Patent – Guarantees intellectual property security and a reliable long-term supply.
- Superior Stability at 37°C for 3 Days – Provides unmatched operational flexibility and experimental convenience in cell culture workflows.
- Enables "Weekend-Free" Continuous Culture – Reduces manual handling, lowers contamination risk, and significantly cuts labor and reagent costs.
Synonym
FGF2, BFGF, FGFB, FGF basic, HBGF-2
Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 16.5 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Host Cell Protein
<0.5 ng/µg of protein tested by ELISA.
Host Cell DNA
<0.02 ng/μg of protein tested by qPCR.
Sterility
Negative
Mycoplasma
Negative
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human FGF basic Superior Stable Mutant Protein, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human FGF basic Superior Stable Mutant Protein, premium grade (Cat. No. BFF-H5113) is more than 95% and the molecular weight of this protein is around 13-21 kDa verified by SEC-MALS.
Report
Heat Stability
Recombinant Human FGF basic Superior Stable Mutant Protein Induces Proliferation of NIH-3T3 Mouse Fibroblast Cells. (A) Human FGF basic Superior Stable Mutant Protein, premium grade (Cat. No. BFF-H5113) or (B) wild-type (WT) Human FGF basic Protein, premium grade (Cat. No. BFF-H4117), were either untreated or incubated in culture media at 37°C for 3 days. Following 3 days of treatment at 37°C, Recombinant Human FGF basic Superior Stable Mutant Protein retained activity comparable to the untreated heat-stable variant, demonstrating its enhanced thermal stability. In contrast, the WT Recombinant Human FGF basic Protein exhibited significant activity loss, indicating inferior thermal stability.
100 ng/mL Superior Stability for Recombinant Human FGF basic Superior Stable Mutant Protein (Cat. No. BFF-H5113) or (B) wild-type (WT) Human FGF basic Protein, premium grade (Cat. No. BFF-H4117), were incubated in culture media at 37°C for 0h, 8h, 24h, 48h and 72h. The concentration of residual FGF2 was detected by resDetect™ Human FGF2 ELISA Kit (Residue Testing) (Cat. No. RES-A009).
Following 72h of treatment at 37°C, Recombinant Human FGF basic Superior Stable Mutant Protein retained higher concentration comparable to the WT FGF2 protein, demonstrating its enhanced thermal stability. In contrast, the WT Recombinant Human FGF basic Protein exhibited significant concentration loss, indicating inferior thermal stability.
Bioactivity-CELL BASE
Human FGF basic Superior Stable Mutant Protein, premium grade (Cat. No. BFF-H5113) stimulates proliferation of NIH/3T3 cells. The specific activity of Human FGF basic Superior Stable Mutant Protein, premium grade is > 1.60 x 10^7 IU/mg, which is calibrated against Basic Fibroblast Growth Factor WHO International Standard (NIBSC code: 90/712) (QC tested).
Protocol
Bioactivity-Stem Cell Culture
100 ng/mL of either Recombinant Human FGF basic Superior Stable Mutant Protein (Cat. No. BFF-H5113, designated as HS-FGF2) or wild-type (WT) Human FGF basic Protein of premium grade (Cat. No. BFF-H4117, designated as WT-FGF2) was added to the iPSC culture system. The culture protocol involved daily medium replacement or a reduced feeding schedule with medium changes every 2 days. Cell counts were assessed via AO/PI staining from passage 1 to passage 3.
The results indicated that the Recombinant Human FGF basic Superior Stable Mutant Protein significantly promoted stem cell proliferation, maintaining high cell numbers even under both daily feeding and the reduced 2-day feeding regimen, with performance comparable to that of competitor T. In contrast, the WT Recombinant Human FGF basic Protein showed a marked decrease in cell numbers under the reduced 2-day feeding condition (Data is the average of 3 independent experiments, error bars ± SD).
100 ng/mL of either Recombinant Human FGF basic Superior Stable Mutant Protein (Cat. No. BFF-H5113, designated as HS-FGF2) or wild-type (WT) Human FGF basic Protein of premium grade (Cat. No. BFF-H4117, designated as WT-FGF2) was added to the iPSC culture system. The culture protocol involved daily medium replacement or a reduced feeding schedule with medium changes every 2 days. The expression of stem cell marker genes (OCT4 and SOX2) was detected by FACS and immunofluorescence in passage 3.
The results indicated that the Recombinant Human FGF basic Superior Stable Mutant Protein significantly maintained stem cell self-renewal, maintaining high expression of stem cell markers even under both daily feeding and the reduced 2-day feeding regimens, with performance comparable to that of competitor T. In contrast, the WT Recombinant Human FGF basic Protein showed a marked decrease in stem cell gene expression under the reduced 2-day feeding condition.
100 ng/mL of either Recombinant Human FGF basic Superior Stable Mutant Protein (Cat. No. BFF-H5113, designated as HS-FGF2) or wild-type (WT) Human FGF basic Protein of premium grade (Cat. No. BFF-H4117, designated as WT-FGF2) was added to the iPSC culture system. The culture protocol involved daily medium replacement or a reduced feeding schedule with medium changes every 2 days. The expression of stem cell marker genes (OCT4 and SOX2) was detected by FACS and immunofluorescence in passage 3.
The results indicated that the Recombinant Human FGF basic Superior Stable Mutant Protein significantly maintained stem cell self-renewal, maintaining high expression of stem cell markers even under both daily feeding and the reduced 2-day feeding regimens, with performance comparable to that of competitor T. In contrast, the WT Recombinant Human FGF basic Protein showed a marked decrease in stem cell gene expression under the reduced 2-day feeding condition.
Bioactivity-ELISA
Immobilized Human FGF basic Superior Stable Mutant Protein, premium grade (Cat. No. BFF-H5113) at 2 μg/mL (100 μL/well) can bind Human Glypican 3 Protein, Fc Tag (Cat. No. GP3-H5258) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Immobilized Human FGF basic Superior Stable Mutant Protein, premium grade (Cat. No. BFF-H5113) at 2 μg/mL (100 μL/well) can bind Human Glypican 1, Fc Tag (Cat. No. GP1-H5254) with a linear range of 0.1-6 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Fibroblast growth factor 2
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
4 Details
- Highest Development Stage：
Approved
Contact Us
Drug Candidate Licensing
